Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

The role of imaging studies in predicting time to first treatment and overall survival in high‐count monoclonal B‐cell lymphocytosis
Kosydar, Samuel , Archibald, William J. , Hampel, Paul J. , Call, Timothy G. , Achenbach, Sara J., Rabe, Kari G. , Hanson, Curtis A. , Koehler, Amber B. , Muchtar, Eli , Kenderian, Saad S. , Leis, José F., Schwager, Susan M., Wang, Yucai , Hilal, Talal , Parrondo, Ricardo D , Shi, Min , Parikh, Sameer A , Chaffee, Kari G. , Kenderian, Saad Sirop , Muchtar, E , Kosydar, Samuel R , Achenbach, Sara J., Wang, Yucai , Roeker, Lindsey E. , Hilal, Talal , Tsang, Mazie , Braggio, Esteban , Slager, Susan L. , Kay, Neil E. , Parikh, Sameer A.

Mayo Clinic

British Journal of Haematology | July 16, 2025 | Volume: 207 | Issue: 3 | Pages: 860-868

10.1111/bjh.70009 | PMID 40664436 Get It

SummaryIn individuals with high‐count monoclonal B‐cell lymphocytosis (MBL), we investigated if lymphadenopathy or splenomegaly found by imaging was associated with shorter time to first chronic lymphocytic leukaemia (CLL) therapy (TTFT) and overall survival (OS). Individuals with MBL seen at Mayo Clinic (2002–2019) were retrospectively divided into three cohorts based on imaging studies within 1 year of diagnosis: no imaging studies (Cohort A); imaging with no evidence of lymphadenopathy/splenomegaly (Cohort B); imaging with evidence of lymphadenopathy/splenomegaly (Cohort C). We compared baseline characteristics, TTFT and OS across the MBL cohorts to a cohort of individuals with small lymphocytic lymphoma (SLL). A total of 1078 patients were included: 640 with MBL and 438 with SLL. Compared to Cohort B, individuals in Cohort C were more likely to have unmutated immunoglobulin heavy chain variable region (IGHV) (43% vs. 25% p = 0.016), high‐risk fluorescence in situ hybridization (FISH) (del17p and del11q in 15% vs. 4%, p = 0.038) and higher expression of CD38 (31% vs. 16%; p = 0.011). After adjusting for sex and CLL‐International Prognostic Index (IPI), lymphadenopathy/splenomegaly was associated with a shorter TTFT (hazard ratio [HR] = 2.04, 95% confidence interval [CI]: 1.02–4.04, p = 0.042) but not OS (HR = 1.09, 95% CI: 0.62–1.92, p = 0.775). Lymphadenopathy/splenomegaly on imaging in individuals with high‐count MBL is associated with a more unfavourable risk profile and shorter time to first CLL‐directed therapy.
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
Brooks, Taylor , Zabor, Emily C. , Bedelu, Yohanna B., Yang, Xi , Karimi, Yasmin , Nedved, Adrienne, Wang, Yucai , Dave, Nikita, Baron, Margaret Kelsey , Trotier, Daniel, Miller, Jordan A. , Reinert, Catherine, Schwarz, Tenley, Salafian, Kiarash , Ayers, Emily C. , McKenna, Marshall, Tiger, Yun Kyoung , Sears-Smith, Megan , Peterson, Chelsea , Khan, Cyrus, Bliven, Sean Patrick , Narkhede, Mayur , Gibson, Alyssa, Munoz, Javier, Smith, Stephen D. , Hernandez‐Ilizaliturri, Francisco J. , Chinyengetere, Fadzai, Davé, Sandeep S. , Abdel-Razeq, Nayef , Hill, Brian T. , Brooks, Taylor R , Karimi, Yasmin H , Baron, Kelsey , Trotier, Daniel C , Pophali, Priyanka , Grover, Natalie S , Major, Ajay , Salafian, Kiarash , Ayers, Emily C , Brody, Joshua D , Sears-Smith, Megan , Peterson, Chelsea , Bliven, Sean P , Garza-Morales, Rodolfo , Ho, Carrie , Smith, Stephen D , Niu, Alex , Moustafa, Muhamad Alhaj , Wang, Yucai , Landsburg, Daniel J. , Hu, Boyu , Pophali, Priyanka A. , Grover, Natalie S. , Major, Ajay , Patel, Krish , Sundaram, Suchitra , Brody, Joshua , Ghosh, Nilanjan , Kline, Justin Paul , Munoz, Javier, Garza-Morales, Rodolfo , Niu, Alex , Moustafa, Muhamad Alhaj , Caimi, Paolo F.

Mayo Clinic

Blood | July 15, 2025 | Volume: 146 | Issue: 18 | Pages: 2177-2188

10.1182/blood.2025029117 | PMID 40663785 Get It

Abstract Epcoritamab and glofitamab are CD20-directed bispecific antibodies (BsAbs) approved in the United States for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Limited data exist for patients treated outside of trials. Patients with R/R DLBCL receiving commercial epcoritamab or glofitamab between 1 January 2023 and 15 October 2024 were collected from 21 United States institutions. Among 245 patients, 156 received epcoritamab and 89 received glofitamab, 113 were refractory to front-line therapy, 40 had MYC and BCL2 and/or BCL6 rearrangements, 147 received prior chimeric antigen receptor T-cell therapy, and 174 patients would have been ineligible for registrational trials. The overall response rate (ORR) for epcoritamab and glofitamab was 51% (23% complete response, [CR]) and 53% (30% CR), respectively. Median progression-free survival (PFS) was 2.6 months (95% confidence interval [CI], 2.0-3.8 months), and median overall survival (OS) was 7.8 months (95% CI, 6.2-11.0 months). The 6-month PFS was 36% (95% CI, 30-44) and the 6-month OS was 60% (95% CI, 54-67). Both trial ineligibility and undetectable CD20 pre-BsAbs portended shorter PFS and OS. Of 17 individuals with paired biopsies, 15 (88.2%) lost CD20 expression after BsAbs with a median time to progression of 3.7 months. This analysis including patients with R/R DLBCL shows the ORR to CD3/CD20 BsAbs was comparable to pivotal trials, although PFS and OS were lower. Baseline undetectable levels of CD20 were associated with poor outcomes. These results demonstrate the activity of BsAbs in R/R DLBCL, and underscore the importance of target antigen expression.
Medical physicist should be a planner in the treatment planning process
Prah, D.E. , Rong, Yi , Prah, Douglas E , Rong, Yi , Wang, Dongxu

Mayo Clinic

Journal of Applied Clinical Medical Physics | July 15, 2025 | Volume: 26 | Issue: 7 | Pages: No page available

10.1002/acm2.70185 | PMID 40660908 Get It

Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
Chen, Charles D., Jack, Clifford R. , Koeppe, Robert, Hornbeck, Russ C. , Koudelis, Deborah, Keefe, Sarah , Aggarwal, Neelum T. , Bird, Thomas D. , Black, Sandra E., Chhatwal, Jasmeer P. , Day, Gregory S. , Farlow, Martin R. , Gauthier, Serge , Honig, Lawrence S., Xiong, Chengjie , Masellis, Mario, Méndez, Patricio Chrem, Ringman, John M. , Snider, B. Joy, Salloway, Stephen, Dyck, Christopher H. van , Klein, Gregory , Clifford, David B. , Hassenstab, Jason , Mills, Susan L., Perrin, Richard J., Supnet, Charlene , Wang, Guoqiao , Xiong, Chengjie , Team, for the DIAN‐TU Study, Jack, Clifford R , Day, Gregory S , Xiong, Chengjie , Chen, Charles D , Hassenstab, Jason , Supnet-Bell, Charlene , McCullough, Austin , Gordon, Brian A. , Joseph‐Mathurin, Nelly , McKay, Nicole S. , Hobbs, Diana A. , Flores, Shaney , Allegri, Ricardo , Berman, Sarah , Black, Sandra E. , Brooks, William S. , Fox, Nick C. , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Jucker, Mathias , Masters, Colin L. , Schofield, Peter R. , Shimada, Hiroyuki , Suzuki, Kazushi , Cruchaga, Carlos , Li, Yan , McDade, Eric , Morris, John C. , Bateman, Randall J. , Benzinger, Tammie L.S. , Team, for the DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | July 15, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70347 | PMID 40660741 Get It

Abstract INTRODUCTION Monoclonal anti‐amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD). METHODS In the DIAN‐TU‐001 trial, 92 carriers received gantenerumab or placebo and underwent serial neuroimaging assessments including [ 11 C]‐Pittsburgh compound‐B (PiB) positron emission tomography (PET), [ 18 F]‐fluoro‐2‐deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI). RESULTS Gantenerumab significantly reduced PiB‐PET uptake overall and in most regions and showed no changes in FDG‐PET or MRI measures. Drug effects were associated with baseline PiB‐PET uptake, and the largest effects occurred in medial regions. DISCUSSION Treated DIAD participants, and especially those with higher amyloid burden, showed a decrease in PiB‐PET uptake, which was more pronounced in the basal ganglia and medial frontal structures. These results may inform patient response and future drug trial design. Highlights Gantenerumab unevenly decreased Aβ burden as measured by PiB‐PET across brain regions. The strongest decrease in PiB‐PET uptake was in basal ganglia and medial frontal structures. Variable drug effect on Aβ was partly due to the amount of burden present before treatment. There was no regional effect on FDG‐PET metabolism or MRI volumetrics after 4 years.
A Systematic Review Supporting the Clinical Practice Guidelines on the Management of Preexisting Diabetes and Pregnancy
Nofal, Alaa Al , Benkhadra, Khalid, Abbas, Alzhraa Salah , Nduwimana, Marie-Joy, Al-Kordi, Mohammad, Allababidi, Adel Kabbara , Wyckoff, Jennifer , Lapolla, Annunziata , Al Nofal, Alaa , Abbas, Alzhraa, Murad, M Hassan , Abbas, Alzhraa Salah , Prokop, Larry J. , Wang, Zhen , Murad, M. Hassan

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 13, 2025 | Volume: 110 | Issue: 9 | Pages: e2811-e2832

10.1210/clinem/dgaf289 | PMID 40652449 Get It

Abstract Context Women with preexisting diabetes mellitus (PDM) are at increased risk of pregnancy-related complications. Objective To summarize the available supporting evidence for the Endocrine Society guidelines about management of PDM in pregnancy. Data Sources MEDLINE, EMBASE, Scopus, and other sources through February 2025. Study Selection Studies were selected by pairs of independent reviewers. Data Extraction Data were extracted by pairs of independent reviewers. Data Synthesis We included 17 studies. Meta-analysis showed no significant difference between hybrid closed-loop insulin pump (HCL) and standard of care regarding time in range (TIR), time above range (TAR), and time below range (TBR). HCL had better overnight TIR and TBR. For women with type 2 diabetes mellitus (T2DM), intermittent use of continuous glucose monitoring (CGM) was not associated with a significant change in the risk of large for gestational age (LGA) neonates (2 randomized controlled trials [RCTs], 102 patients). Adding metformin to insulin was associated with a lower risk of LGA (2 RCTs, 1126 patients). Three retrospective studies (1724 patients) suggested increased neonatal complications when delivery was induced before 39 weeks of gestation (particularly before 38 weeks) in women with preexisting type 1 (T1DM) and T2DM, although this evidence was subject to likely confounding. One retrospective study showed no increase in neonatal complications with periconceptional exposure to glucagon-like peptide-1 receptor agonists. We could not identify comparative studies assessing a screening question about the possibility of pregnancy or a carbohydrate restrictive diet. Conclusion This systematic review addresses various aspects of managing PDM in pregnancy and will support the development of the Endocrine Society guidelines.
Brain atrophy patterns in anti-IgLON5 disease
Yogeshwar, Selina , Bartels, Frederik , Muñiz‐Castrillo, Sergio , Picard, Géraldine , Bernard, E , Ζεκερίδου, Αναστασία , Ringelstein, Marius , Kraft, Andrea , Kovac, Stjepana , Wandinger, Klaus‐Peter , Vries, Juna M. de, Boon, Agnita J.W. , Veenbergen, Sharon , Penner, Loana , Gaig, Carles , Sabater, Lídia , Santamaría, Joan , Prüß, Harald , Lewerenz, Jan , Irani, Sarosh R. , Mignot, Emmanuel , Titulaer, Maarten J. , Ayzenberg, Ilya , Francillard, Aurélie Méneret Isabelle, Renard, Dimitri , Desestret, Virginie, Capet, Nicolas , Davion, Jean‐Baptiste , Boucher, Julie, Combres, Helene, Rafiq, Marie , Bonneville, Fabrice , Cumin, Marina, Soulages, Antoine , Compoint, Mathilde, Moulin, Maximilien , Berling, Édouard , Garrigues, Eve, Chanson, Marine, Bourg, Veronique , Giordana, Caroline, Benoit, Jeanne , Flabeau, Olivier, Derivoyre, Emmanuelle, Ryckewaert, Gilles, Alberto, Tifanie, Carrière, Nicolas , Mostoufizadehs, Sohrab, Barbay, Mélanie , Bénaiteau, Marie , Sellal, François , Casez, Olivier, Bruel, Cédric , Kalifa, L G, Rusu, Elena Camelia, Demortière, Sarah , Maarouf, Adil, Wang, Adrien , Brasset, Adelaide, Attal, Arthur, Demourant, Céline, Houéto, Jean‐Luc , Brueggemann, Norbert, Dargvainiene, Justina , Oy, Ulrich Hofstadt‐van , Nagel, Michael , Urbanek, Christian, Schroeder, Ina, Schramm, Peter , Tonner, Silke, Seitz, Caspar , Tschernatsch, Marlene , Chung, Ha‐Yeun , Wickel, Jonathan , Schoeberl, Florian, Macher, Stefan , Simabukuro, Mateus Mistieri , Zittel-Dirks, Simone, Wildemann, Brigitte , Kothaj, Ján, Ordás, Carlos , Angstwurm, Klemens , Tomás, Ángela Milán, Bastida, Antonio Martin, Quintas, Sonia , Kimura, Akio , Akira, Takekoshi, Scheller-Nissen, Mette, Hartmann, Christian, Bastiaansen, Danielle, Steenhoven, Robin van, Schwichtenberg, Katia , Yogeshwar, Selina M , Grüter, Thomas , Muñiz-Castrillo, Sergio , Melzer, Nico , Leypoldt, Frank , Pittock, S J , Höftberger, Romana , Howe, Charles L , Irani, Sarosh R , Mignot, Emmanuel , Honnorat, Jérôme , Finke, Carsten , Titulaer, Maarten J , Crijnen, Y S , Heidbreder, Anna , Geis, Christian , Blaabjerg, Morten , Pittock, Sean J. , Graus, Francesc , Dalmau, Josep , Schreiner, Bettina , Honnorat, Jérôme , Méneret, Aurélie , Desestret, Virginie , Boucher, Julie, Zéphir, Hélène , Damier, Philippe , Combres, Hélène, Cumin, Marina, Compoint, Mathilde, Chanson, Marine, Vogrig, Alberto , Casez, Olivier , Kalifa, Laurette, Rusu, Elena Camelia, Carra‐Dallière, Clarisse , Cluse, Florent , Brueggemann, Norbert, Seifert‐Held, Thomas , Villacieros‐Álvarez, Javier , Berger–Sieczkowski, Evelyn , Tambasco, Nicola , Nigro, Pasquale , Iorio, Raffaele , Ono, Yoya , Shimohata, Takayoshi , Bastiaansen, Danielle

Mayo Clinic

Brain | July 12, 2025 | Volume: 149 | Issue: 3 | Pages: 884-896

10.1093/brain/awaf256 | PMID 40650880 Get It

Abstract Anti-IgLON5 disease is an autoimmune encephalitis that presents with a heterogenous clinical phenotype, including sleep disorders, movement abnormalities and bulbar involvement. It is characterized by autoantibodies against IgLON5, 85% association with HLA-DQB1*05:∼ and a brainstem-dominant tauopathy. Cellular and murine models report pathogenic effects of the autoantibodies, and neurodegenerative factors suggest progressive atrophy as a common sequela. However, evidence from in vivo patient data and long-term follow-up is limited, and the degree of progression remains elusive. In this multicentre study, clinical and brain MRI data were collected from 127 patients across 12 countries to investigate the relationships between clinical presentations and the development of distinct brain atrophy patterns. Our data show that most patients develop a complex multisystem phenotype as the disease progresses; however, neuromuscular manifestations rarely emerge at later disease stages. By comparison to healthy controls, this disease presents with severe substructure-specific atrophy, especially affecting the hypothalamus, brainstem, accumbens and basal ganglia, which, in age-independent analyses, show significant ventricular enlargement and also suggest progression of brainstem atrophy over the disease course. Moreover, the focality of atrophy was functionally linked to specific symptoms, with more severe involvement of the basal ganglia in patients with movement disorders, and greater atrophy in the hippocampus and thalamus in patients with cognitive impairment. Taken together, our results provide evidence of distinct atrophy patterns in anti-IgLON5 disease, which closely mirror sites of pathophysiologic processes, including autoantibody binding and tau deposition. Our data emphasize the brainstem as the pathophysiological hub of the disease and provide normative data for the incorporation of atrophy measurements into routine clinical assessments and future treatment studies to monitor disease trajectory and evaluate future treatment strategies.
Revolutionizing nephrocalcinosis treatment: IL ‐10 engineered macrophages as a novel therapeutic approach
Zhao, Wenlei , Wang, Kailong, Chen, Hairui , Xu, Junnan , Wen, Lequan , Wu, Yan , Chen, Weihao , Liu, Yanzhong, Zhang, Luo , Zhang, Xu , Mai, H. , Mai, Haixing , Liu, Haitao , Liu, Yanzhong, Zhang, Jiqing , Lieske, John C.

Mayo Clinic

Bioengineering & Translational Medicine | July 11, 2025 | Volume: 11 | Issue: 1 | Pages: No page available

10.1002/btm2.70047 | PMID 41573378 Get It

Abstract Nephrocalcinosis provides a nidus for stone formation and is strongly linked to renal injury and chronic kidney disease. Although the crucial role of macrophages in the formation and progression of calcium oxalate (CaOx) crystals has long been widely recognized, finding effective immunotherapies for nephrocalcinosis remains a challenge. In this study, we described an innovative macrophage‐based method that delivers interleukin‐10 (IL‐10) into the kidney, reduces the deposition of CaOx crystals, and alleviates renal injury in a mouse model of glyoxylate‐induced CaOx. Compared with recombinant IL‐10 direct injection, the macrophage‐based method has the advantages of biocompatibility and sustaining action. We found that the transplantation of engineered macrophages via the tail vein significantly reduced the volume of crystals in the kidney, thereby alleviating the kidney injury caused by crystal. In mechanistic studies, IL‐10‐secreting macrophages inhibited crystal formation and promoted crystal clearance by promoting macrophage M2 polarization, exerting a protective effect on renal tissue. Our data suggest that macrophage‐based delivery of IL‐10 to the kidney can be a potential treatment method for nephrocalcinosis.
Atomic-resolution structure of a chimeric Powassan tick-borne flavivirus
Das, Sayan , Narayanan, Anoop , Wang, Anqi , Moustafa, Ibrahim M. , Cho, Sung Hyun , Mitzel, Dana , Jose, Joyce , Hafenstein, Susan , Hafenstein, Susan L

Mayo Clinic

Science Advances | July 9, 2025 | Volume: 11 | Issue: 28 | Pages: No page available

10.1126/sciadv.adw7700 | PMID 40632869 Get It

Powassan virus (POWV) is an emerging tick-borne flavivirus for which no vaccine or antiviral treatment exists. The incidence of human infections of POWV in North America has been increasing because of the expanding distribution of the tick vector Ixodes scapularis that transmits POWV to humans. To mitigate the dangers of handling a risk group 3 human pathogen, a chimeric virus was constructed from the genetic backbone of a yellow fever virus vaccine strain 17D (YFV-17D) and the external structural proteins of POWV lineage II. The chimera had a comparable phenotype as POWV. The atomic resolution of yellow fever virus-Powassan virus chimera (yPOWV) structure was built without ambiguity, revealing surface glycans and lipid pocket factors. The similarity to other flavivirus structures and the phenotype similar to YFV-17D suggest that there could be future potential as a vaccine candidate.
Development of a Hepatocyte‐Specific Temporal Genetic Mouse Model Using Albumin Promoter‐Driven FlpER2 Expression
Wang, Bin , Wang, Jiale , Liu, Yang , He, Gordon, Jahan‐mihan, Yasmin , Hu, Jie , Li, Audrey , Bi, Yan , Ji, Baoan , Wang, Yuxi, Muhammad, Faheem, Wang, Jiale , Wang, Bin , He, Gordon, Wang, Di , Faheem, Muhammad

Mayo Clinic

genesis | July 9, 2025 | Volume: 63 | Issue: 4 | Pages: No page available

10.1002/dvg.70022 | PMID 40631533 Get It

ABSTRACTTissue‐specific gene manipulation using Cre/loxP or Flp/frt recombination systems is a cornerstone of genetically engineered mouse models. In this study, we aim to develop a novel hepatocyte‐specific, tamoxifen‐inducible Flp mouse line. BAC (bacterial artificial chromosome)‐Alb(albumin)‐FlpER2(estrogen receptor ligan binding domain) was developed by inserting IRES‐FlpER2 cDNA between the translation stop codon and 3′‐UTR of the mouse albumin gene in a bacterial artificial chromosome. Upon tamoxifen induction in mice crossed with reporter lines, western blotting, immunohistochemistry, immunofluorescence staining, and X‐gal staining (5‐bromo‐4‐chloro‐3‐indolyl‐β‐D‐galactopyranoside Staining) were used to verify the recombination efficiency and specificity of this mouse model. Recombination was highly efficient and specific in hepatocytes, with no recombination detected in intrahepatic cholangiocytes or other organs in this mouse model. We generated a new tamoxifen‐induced hepatocyte‐specific mouse model with highly efficient recombination specifically in hepatocytes, and this model can be used to generate tumor model lines.
GLP-1 Receptor Agonist Use Is Associated With Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth
Fredrick, Thomas , Ospina-Velasquez, Luis, Fredrick, Thomas W , Damianos, John , Jin, Mauricio F. , Wang, Xiao Jing

Mayo Clinic

Foregut: The Journal of the American Foregut Society | July 9, 2025 | Volume: 5 | Issue: 4 | Pages: 433-437

10.1177/26345161251353437 Get It

Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP1RAs) are increasingly used to treat obesity and other metabolic conditions; however, they are known to inhibit gastrointestinal motility. Since gastrointestinal microbial overgrowth (MO) can arise in states of intestinal stasis, we sought to investigate the potential association between GLP1RA use and MO. Methods: We analyzed data from 99 patients prescribed GLP1RAs who subsequently underwent testing for MO via intestinal aspirate culture or glucose or lactulose breath tests. Results: Most patients had diabetes. Among patients who underwent culture, 76.2% tested positive for small intestinal bacterial overgrowth (SIBO) at a threshold of ≥10³ CFU/mL, with a significant association found between proton pump inhibitor (PPI) use and SIBO. At ≥10 5 CFU/mL, 33.3% tested positive for SIBO, and neither PPI use nor surgical history was associated. Breath testing revealed a 30.6% positivity rate for MO, predominantly characterized by intestinal methanogen overgrowth (IMO). There was no association between control of diabetes and positive MO tests. Conclusion: GLP1RA use is associated with SIBO, although diabetes may be a confounder.